Robert Paproski, PhD

Contact

Department of Oncology
University of Alberta
Edmonton, Alberta

Email: Joseph.Roberts@albertahealthservices.ca

Postdoctoral Fellow, Dr. John Lewis Laboratory and Dr. Roger Zemp Laboratory, Department of Oncology, University of Alberta

My research focuses on developing novel therapeutic and diagnostic procedures for cancer using ultrasound. Ultrasound in the presence of small gas microbubbles has been shown to create pores in cell membranes, allowing therapeutic genes or biomarkers to enter or leave cells, respectively. We are currently trying to understand what biomarkers are liberated from sonicated cells with an emphasis on detecting released microparticles which can be detected and enumerated with the Apogee A50 micro flow cytometer.

We are also developing novel ultrasound contrast agents that can accumulate in tumors at greater levels than current ultrasound contrast agents (i.e., microbubbles which remain in the vasculature due to their large size at ~2 microns). These smaller ultrasound contrast agents, called nanodroplets, have liquid perfluorocarbon cores that, in the presence of high pressure ultrasound, can phase change into gas microbubbles which provides contrast in ultrasound imaging. These nanodroplets may increase our ability to detect tumors with ultrasound imaging.


Relevant Publications

Forbrich A, Paproski RJ, Hitt M, Zemp RJ. Microbubble-Enhanced Ultrasound Liberation of mRNA Biomarkers In Vitro. Ultrasound in Medicine & Biology. 39(6): 1087-93, 2013.

Paproski RJ, Yao S, Favis N, Evans D, Young JD, Cass CE, Zemp RJ. Human concentrative nucleoside transporter 3 transfection with ultrasound and microbubbles in nucleoside transport deficient HEK293 cells greatly increases gemcitabine uptake. PLoS One. 8(2):e56423, 2013.

Wiebe LI, Sun W, Zhou A, Yang J, Sjuvarsson EV, Eriksson S, Paproski RJ, Cass CE, Kumar P, Knaus EE. Biochemistry and biology of 2′-Fluoro-2′-deoxythymidine (FT), a putative highly selective substrate for thymidine kinase type 2 (TK2). Curr Radiopharm. 5(1): 38-46, 2012.

Paproski RJ, Forbrich AE, Wachowicz K, Hitt MM, Zemp RJ. Tyrosinase as a dual reporter gene for both photoacoustic and magnetic resonance imaging. Biomed Opt Express. 2(4): 771-80, 2011.

Paproski RJ, Forbrich AE, Harrison T, Hitt MM, Zemp RJ. Photoacoustic imaging of gene expression using tyrosinase as a reporter gene. Proc. SPIE 7899, 78991H, 2011.

Paproski RJ, Wuest M, Jans HS, Graham K, Gati WP, McQuarrie S, McEwan A, Mercer J, Young JD, Cass CE. Biodistribution and uptake of 3′-deoxy-3′-fluorothymidine in ENT1-knockout mice and in an ENT1- knockdown tumor model. J Nucl Med. 51(9): 1447-55, 2010.

Paproski RJ, Young JD, Cass CE. Predicting gemcitabine transport and toxicity in human pancreatic cancer cell lines with the positron emission tomography tracer 3′-deoxy-3′-fluorothymidine. Biochem Pharmacol. 79(4): 587-95, 2010.

Paproski RJ, Ng AM, Yao SY, Graham K, Young JD, Cass CE. The Role of Human Nucleoside Transporters in Uptake of 3′-Deoxy-3′-Fluorothymidine. Mol Pharmacol. 74(5): 1372-80, 2008.

Paproski RJ, Visser F, Zhang J, Tackaberry T, Damaraju V, Baldwin SA, Young JD, Cass CE. Mutation of Trp29 of human equilibrative nucleoside transporter 1 alters affinity for coronary vasodilator drugs and nucleoside selectivity. Biochem J. 414(2): 291-300, 2008.

Emami S, Kumar P, Yang J, Kresolic Z, Paproski R, Cass C, McEwan AJ, Wiebe LI. Synthesis, transportability and hypoxiaselective binding of 1-beta-D-(5-Deoxy-5-fluororibofuranosyl)-2-nitroimidazole (beta-5-FAZR), a configurational isomer of the clinical hypoxia marker, FAZA. J Pharm Pharm Sci. 10(2): 237-45, 2007.

Contact

Department of Oncology
University of Alberta
Edmonton, Alberta

Email: Joseph.Roberts@albertahealthservices.ca